Novel hormonal agents in men with metastatic castration resistant prostate cancer and reduced performance status: Experiences of a specialized single center
Abstract Objectives Attaining castration resistance in metastatic prostate cancer (mCRPC) represents a pivotal juncture in the progression of the patient's illness and treatment regimen. Within this therapeutic context, novel hormonal agents (NHA) constitute a fundamental component of pharmacol...
Saved in:
Main Authors: | Thomas Büttner, Philipp Lossin, Stefan Latz, Carolin Jacobs, Philipp Krausewitz, Stefan Hauser |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-12-01
|
Series: | Aging Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/agm2.12372 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01) -
HORMONE THERAPY WITH USAGE OF AGONISTS AND ANTAGONISTS OF LUTEINIZING HORMONE RELEASING HORMONE IN PATIENTS WITH PROSTATE CANCER
by: K. M. Nyushko, et al.
Published: (2015-01-01) -
Clinical observations of patients with metastatic castration-resistant prostate cancer living in the Tambov region
by: P. G. Berezin, et al.
Published: (2023-09-01) -
An MRI radiomics model for predicting a prostate-specific antigen response following abiraterone treatment in patients with metastatic castration-resistant prostate cancer
by: Yi Wu, et al.
Published: (2025-01-01) -
Long-term ultrasonographic changes of the canine prostate gland after castration
by: Stefano Spada, et al.
Published: (2025-01-01)